Fintech PR
Group Life Insurance Market to Reach $348.38 Billion, Globally, by 2032 at 10.7% CAGR: Allied Market Research
Increase in understanding of the importance of financial stability & employee well-being, and technological advancements that speed up insurance processes drive the growth of the group life insurance market.
WILMINGTON, Del., Feb. 14, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Group Life Insurance Market by Type (Contributory Plans and Non-contributory Plans), Enterprise Size (Large Enterprises and Small & Medium-sized Enterprises), and Distribution Channel (Direct Sales, Brokers/Agents, Banks, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2032″. According to the report, the global group life insurance industry generated $127.6 billion in 2022, and is anticipated to generate $348.38 billion by 2032, witnessing a CAGR of 10.7% from 2023 to 2032.
Request Research Report Sample & TOC: https://www.alliedmarketresearch.com/request-sample/A14963
Prime determinants of growth
A growth in understanding of the importance of financial stability and employee well-being has fueled the popularity of group life insurance, leading to an increase in adoption of these policies among organizations. Furthermore, legal assistance and tax benefits for employers offering group life insurance contribute to the group life insurance market growth. On the contrary, technological advancements that speed up insurance operations, and the potential for product innovation to meet the diverse range of customer needs are expected to provide lucrative growth opportunities to the group life insurance market.
Report coverage & details:
|
Report Coverage |
Details |
|
Forecast Period |
2022–2032 |
|
Base Year |
2022 |
|
Market Size in 2022 |
$127.6 billion |
|
Market Size in 2032 |
$348.38 billion |
|
CAGR |
10.7 % |
|
Segments Covered |
Type, enterprise size, distribution channel, and region. |
|
Drivers |
Growth in importance of financial stability and employee well-being Legal support and tax benefits |
|
Opportunity |
Technological advancements |
|
Restraints |
Regulatory changes and compliance complexities Interest rate fluctuations |
Procure Complete Report (245 Pages PDF with Insights, Charts, Tables, and Figures) @ https://bit.ly/3UG1IcT
The non-contributory plans segment to maintain its leadership status throughout the forecast period
On the basis of type, the non-contributory plans segment held the highest market share in 2022, accounting for nearly three-fourths of the global group life insurance market revenue, and is estimated to maintain its leadership status throughout the forecast period. This is attributed to the fact that this plan is employer-funded which relieves employees from premium contributions. However, the contributory plans segment is projected to manifest the highest CAGR of 13.4% from 2023 to 2032. The growth of contributory plans in the group life insurance market is gaining popularity because it involves both employer and employees sharing the premium costs.
The large enterprises segment to maintain its leadership status throughout the forecast period
On the basis of enterprise size, the large enterprises segment held the highest market share in 2022, accounting for more than two-thirds of the global group life insurance market revenue, and is estimated to maintain its leadership status throughout the forecast period. The growth of group life insurance in large enterprises is gaining popularity because it offers a cost-effective way to provide valuable benefits to a large number of employees. However, the small and medium-sized enterprises segment is projected to manifest the highest CAGR of 13.7% from 2023 to 2032. This is attributed to the fact that as SMEs often face budget constraints, group life insurance provides a competitive employee benefit without imposing a significant financial burden on the company.
The brokers/agents segment to maintain its leadership status throughout the forecast period
On the basis of distribution channel, the brokers/agents segment held the highest market share in 2022, accounting for around two-fifths of the global group life insurance market revenue, and is estimated to maintain its leadership status throughout the forecast period. This is attributed to the fact that these professionals have expertise in navigating the complexities of insurance offerings. However, the banks segment is projected to manifest the highest CAGR of 14.4% from 2023 to 2032, as banks provide competitive rates and simplified administrative processes, making it an accessible option for certain businesses.
Get Customized Reports with your Requirements: https://www.alliedmarketresearch.com/request-for-customization/A14963
North America to maintain its dominance by 2032
On the basis of region, North America held the highest market share in terms of revenue in 2022, accounting for more than one-third of the group life insurance market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to increase in awareness and importance of financial security and the ease of access to coverage within the workplace contributes to its popularity. However, Asia-Pacific is expected to witness the fastest CAGR of 14.6% from 2023 to 2032. This is attributed to the convenience of group policies, with simplified underwriting processes and cost-sharing benefits, attracting employers seeking to provide coverage for their workforce.
Leading Market Players: –
- MetLife Services and Solutions, LLC
- American International Group, Inc.
- Prudential Financial, Inc.
- Allianz
- AXA SA
- Zurich
- The Manufacturers Life Insurance Company
- Sun Life Assurance Company of Canada
- Cigna Healthcare
- New York Life Insurance Company
The report provides a detailed analysis of these key players in the global group life insurance market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Inquiry before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/A14963
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the group life insurance market analysis from 2022 to 2032 to identify the prevailing group life insurance market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- The Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the group life insurance market segmentation assists to determine the prevailing group life insurance market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes an analysis of the regional as well as group life insurance market trends, key players, market segments, application areas, and market growth strategies.
Group Life Insurance Market Report Highlights
By Type
- Contributory Plans
- Non-contributory Plans
By Enterprise Size
- Large Enterprises
- Small and Medium-sized Enterprises
By Distribution Channel
- Direct Sales
- Brokers/Agents
- Banks
- Others
By Region
- North America (U.S., Canada)
- Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
- Latin America (Brazil, Argentina, Rest of Latin America)
- Middle East and Africa (Gcc Countries, South Africa, Rest of Middle East And Africa)
Trending Reports in BFSI Industry (Book Now with 10% Discount):
Liability Insurance Market Size, Share, Competitive Landscape and Trend Analysis Report by Coverage Type (General Liability Insurance, Professional Liability Insurance, Insurance for Directors and Officers), by Enterprise Size (Medium-sized Enterprises, Large Enterprises, Small Enterprises), by Application (Commercial, Personal): Global Opportunity Analysis and Industry Forecast, 2021-2031.
Disability Insurance Market Size, Share, Competitive Landscape and Trend Analysis Report by Insurance Type (Employer Supplied Disability Insurance, Individual Disability Insurance, High Limit Disability Insurance, Business Overhead Expense Disability Insurance, Others), by End User (Government, Enterprise, Individual), by Coverage Type (Short Term Disability Insurance, Long Term Disability Insurance): Global Opportunity Analysis and Industry Forecast, 2021-2031.
Insurance Fraud Detection Market Size, Share, Competitive Landscape and Trend Analysis Report by Component (Solution, Services), by Deployment Mode (On-premises, Cloud), by Enterprise Size (Large Enterprises, Small and Medium-sized Enterprises (SMEs)), by Applications (Payment Fraud and Billing Fraud, Identity Theft, Claims Fraud, Money Laundering): Global Opportunity Analysis and Industry Forecast, 2021-2031.
Insurance Analytics Market By Component (Solution and Service), Deployment Type (On-Premises and Cloud), Enterprise Size (Large Enterprises and Small & Medium Enterprises (SMEs)), Application (Claims Management, Risk Management, Customer Management, Sales & Marketing, and Others), End User (Insurance Companies, Government Agencies, and Third-party Administrators, Brokers & Consultancies): Global Opportunity Analysis and Industry Forecast, 2020-2027.
Health Insurance Market Size, Share, Competitive Landscape and Trend Analysis Report by Distribution Channel (Direct Sales, Brokers/Agents, Banks, and Others), Insurance Type (Diseases Insurance and Medical Insurance), Coverage (Preferred Provider Organizations (PPOs), Point of Service (POS), Health Maintenance Organizations (HMOs), and Exclusive Provider Organizations (EPOs)), End User Type (Group and Individuals), and Age Group (Senior Citizens, Adult, and Minors): Global Opportunity Analysis and Industry Forecast, 2021-2028.
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports Insights” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 Usa.
Int’l: +1-503-894-6022
Toll Free: +1-800-792-5285
Uk: +44-845-528-1300
India (Pune): +91-20-66346060
Fax: +1-800-792-5285
[email protected]
Bfsi Blog
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/group-life-insurance-market-to-reach-348-38-billion-globally-by-2032-at-10-7-cagr-allied-market-research-302061807.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News5 days ago
B Lab UK research reveals UK public back change to company law to put people, the planet and profit on more equal footing
-
Latest News4 days ago
Cayman Enterprise City Publishes Socio-Economic Impact Assessment by Economist and Leading Advisor on the Caribbean, Marla Dukharan
-
Latest News5 days ago
Unleash a Wave of Opportunities this May with Bybit
-
Latest News5 days ago
Bankart migrates payment processing to Diebold Nixdorf’s Vynamic Transaction Middleware
-
Latest News3 days ago
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
-
Latest News4 days ago
SANY Heavy Industry Reports 2023 Earnings: Overseas Revenue Soars to 60% of Core Business Amid Market Pressures, Signaling Strong Global Expansion
-
Latest News4 days ago
barq and TerraPay Forge a Strategic Partnership
-
Latest News4 days ago
Over 10 innovative CDBC card services launched in six months on OpenWay’s Way4 system